Rhumbline Advisers Kymera Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 62,296 shares of KYMR stock, worth $2.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,296

Previous 64,535 3.47%

Holding current value

$2.54 Million

Previous $1.93 Million 53.06%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$30.16 - $52.4 $67,528 - $117,323	-2,239 Reduced 3.47%	62,296 $2.95 Million
Q2 2024 Aug 01, 2024	BUY	$29.85 - $39.42 $213,218 - $281,577	7,143 Added 12.45%	64,535 $1.93 Million
Q1 2024 May 09, 2024	BUY	$22.9 - $43.57 $89,058 - $169,443	3,889 Added 7.27%	57,392 $2.31 Million
Q4 2023 Feb 08, 2024	SELL	$10.97 - $26.84 $1,360 - $3,328	-124 Reduced 0.23%	53,503 $1.36 Million
Q3 2023 Nov 09, 2023	SELL	$13.9 - $23.88 $236 - $405	-17 Reduced 0.03%	53,627 $745,000
Q2 2023 Aug 08, 2023	SELL	$22.4 - $34.92 $230,339 - $359,082	-10,283 Reduced 16.09%	53,644 $1.23 Million
Q1 2023 May 11, 2023	BUY	$24.84 - $38.75 $67,241 - $104,896	2,707 Added 4.42%	63,927 $1.89 Million
Q4 2022 Feb 14, 2023	BUY	$19.57 - $30.92 $19,433 - $30,703	993 Added 1.65%	61,220 $1.53 Million
Q3 2022 Nov 10, 2022	BUY	$20.91 - $34.27 $111,638 - $182,967	5,339 Added 9.73%	60,227 $1.31 Million
Q2 2022 Aug 11, 2022	BUY	$14.13 - $42.55 $263,948 - $794,834	18,680 Added 51.59%	54,888 $1.08 Million
Q1 2022 May 12, 2022	BUY	$35.3 - $64.68 $87,579 - $160,471	2,481 Added 7.36%	36,208 $1.53 Million
Q4 2021 Feb 10, 2022	BUY	$49.91 - $65.56 $23,657 - $31,075	474 Added 1.43%	33,727 $2.14 Million
Q3 2021 Nov 12, 2021	BUY	$47.8 - $66.66 $272,268 - $379,695	5,696 Added 20.67%	33,253 $1.95 Million
Q2 2021 Aug 05, 2021	BUY	$31.08 - $51.95 $501,662 - $838,524	16,141 Added 141.39%	27,557 $1.34 Million
Q1 2021 May 06, 2021	BUY	$35.64 - $85.46 $32,967 - $79,050	925 Added 8.82%	11,416 $444,000
Q4 2020 Feb 10, 2021	BUY	$28.07 - $87.83 $294,482 - $921,424	10,491 New	10,491 $650,000

Others Institutions Holding KYMR

# of Institutions

184

Shares Held

64.4M

Call Options Held

50.6K

Put Options Held

81.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.23B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Kymera Therapeutics, Inc. Transaction History